MétaCan
Menu
Back to cohort
Record W2741457765 · doi:10.1001/jama.2017.9362

Effect of Oral Methylprednisolone on Clinical Outcomes in Patients With IgA Nephropathy

2017· article· en· W2741457765 on OpenAlexafffund
Jicheng Lv, Hong Zhang, Muh Geot Wong, Meg Jardine, Michelle Hladunewich, Vivekanand Jha, Helen Monaghan, Ming‐Hui Zhao, Sean Barbour, Heather N. Reich, Daniel C. Cattran, Richard J. Glassock, Adeera Levin, David C. Wheeler, Mark Woodward, Laurent Billot, Tak Mao Chan, David W. Johnson, Alan Cass, John Feehally, Jürgen Floege, Giuseppe Remuzzi, Yangfeng Wu, Rajiv Agarwal, Hai-Yan Wang, Vlado Perkovic

Bibliographic record

VenueJAMA · 2017
Typearticle
Languageen
FieldMedicine
TopicRenal Diseases and Glomerulopathies
Canadian institutionsUniversity Health NetworkUniversity of British ColumbiaHealth Sciences CentreSunnybrook Health Science Centre
FundersRenmin Hospital of Wuhan UniversityShengjing HospitalWest China Hospital, Sichuan UniversityCanadian Institutes of Health ResearchPfizer PharmaceuticalsTongji UniversityGenentechFirst Affiliated Hospital of Zhengzhou UniversityGeorge Institute for Global HealthRenji HospitalHebei Medical UniversityBaotou Medical CollegeTongji Medical College, Huazhong University of Science and TechnologyNational Health and Medical Research CouncilNanjing UniversityPeking UniversityMedical Research CouncilZhejiang UniversitySchool of Medicine, Indiana UniversityRelypsaWuhan UniversityHenan UniversityRuijin HospitalUniversity of LeicesterNanjing General Hospital of Nanjing Military CommandZhengzhou UniversityFresenius Medical Care North AmericaUniversity of British ColumbiaEli Lilly and CompanyPfizerCharles Darwin UniversityDiabetes AustraliaHuazhong University of Science and TechnologyJanssen Research and DevelopmentAkebia TherapeuticsDiabetes Australia Research TrustChina Medical UniversitySanofiHenan University of Science and TechnologyHuashan HospitalRebecca L. Cooper Medical Research FoundationOmeros CorporationDavid Geffen School of Medicine, University of California, Los AngelesPeking University People's HospitalNational Institute of Diabetes and Digestive and Kidney DiseasesPostgraduate Institute of Medical Education and Research, ChandigarhQilu Hospital of Shandong UniversitySichuan UniversityShandong UniversityJohns Hopkins UniversityChugai PharmaceuticalGeneral Hospital of People’s Liberation ArmyMenzies School of Health ResearchShanxi Medical UniversityAmgenFudan UniversityPeking University First Hospital
KeywordsMedicineNephropathyRenal functionProteinuriaInternal medicineKidney diseaseGastroenterologyRandomized controlled trialMethylprednisoloneUrologyDiabetes mellitusKidneyEndocrinology

Abstract

fetched live from OpenAlex

Importance: Guidelines recommend corticosteroids in patients with IgA nephropathy and persistent proteinuria, but the effects remain uncertain. Objective: To evaluate the efficacy and safety of corticosteroids in patients with IgA nephropathy at risk of progression. Design, Setting, and Participants: The Therapeutic Evaluation of Steroids in IgA Nephropathy Global (TESTING) study was a multicenter, double-blind, randomized clinical trial designed to recruit 750 participants with IgA nephropathy (proteinuria greater than 1 g/d and estimated glomerular filtration rate [eGFR] of 20 to 120 mL/min/1.73 m2 after at least 3 months of blood pressure control with renin-angiotensin system blockade] and to provide follow-up until 335 primary outcomes occurred. Interventions: Patients were randomized 1:1 to oral methylprednisolone (0.6-0.8 mg/kg/d; maximum, 48 mg/d) (n = 136) or matching placebo (n = 126) for 2 months, with subsequent weaning over 4 to 6 months. Main Outcomes and Measures: The primary composite outcome was end-stage kidney disease, death due to kidney failure, or a 40% decrease in eGFR. Predefined safety outcomes were serious infection, new diabetes, gastrointestinal hemorrhage, fracture/osteonecrosis, and cardiovascular events. The mean required follow-up was estimated to be 5 years. Results: After randomization of 262 participants (mean age, 38.6 [SD, 11.1] years; 96 [37%] women; eGFR, 59.4 mL/min/1.73 m2; urine protein excretion, 2.40 g/d) and 2.1 years' median follow-up, recruitment was discontinued because of excess serious adverse events. Serious events occurred in 20 participants (14.7%) in the methylprednisolone group vs 4 (3.2%) in the placebo group (P = .001; risk difference, 11.5% [95% CI, 4.8%-18.2%]), mostly due to excess serious infections (11 [8.1%] vs 0; risk difference, 8.1% [95% CI, 3.5%-13.9%]; P < .001), including 2 deaths. The primary renal outcome occurred in 8 participants (5.9%) in the methylprednisolone group vs 20 (15.9%) in the placebo group (hazard ratio, 0.37 [95% CI, 0.17-0.85]; risk difference, 10.0% [95% CI, 2.5%-17.9%]; P = .02). Conclusions and Relevance: Among patients with IgA nephropathy and proteinuria of 1 g/d or greater, oral methylprednisolone was associated with an increased risk of serious adverse events, primarily infections. Although the results were consistent with potential renal benefit, definitive conclusions about treatment benefit cannot be made, owing to early termination of the trial. Trial Registration: clinicaltrials.gov Identifier: NCT01560052.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.003
metaresearch head score (Gemma)0.005
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Randomized trial · Consensus signal: Randomized trial
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.003
Threshold uncertainty score0.015

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0030.005
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0010.001
Insufficient payload (model declined to judge)0.0020.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.018
GPT teacher head0.349
Teacher spread0.331 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designRandomized trial
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations530
Published2017
Admission routes2
Has abstractyes

Explore more

Same venueJAMASame topicRenal Diseases and GlomerulopathiesFrench-language works237,207